Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.57)
# 269
Out of 4,435 analysts
129
Total ratings
48.03%
Success rate
40%
Average return
Main Sectors:
Top Industries:
37 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XFOR X4 Pharmaceuticals | Reiterates: Overweight | $5 | $1.01 | +395.05% | 3 | May 31, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $107 → $115 | $40.14 | +186.50% | 8 | May 31, 2024 | |
| CDXS Codexis | Initiates: Overweight | $11 | $3.38 | +225.44% | 1 | May 30, 2024 | |
| IRON Disc Medicine | Reiterates: Overweight | $85 | $33.95 | +150.37% | 5 | May 28, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $3.43 | +104.08% | 12 | May 28, 2024 | |
| SKYE Skye Bioscience | Initiates: Overweight | $21 | $11.61 | +80.88% | 1 | May 23, 2024 | |
| FULC Fulcrum Therapeutics | Initiates: Overweight | $23 | $7.85 | +192.99% | 1 | May 20, 2024 | |
| ETNB 89bio | Reiterates: Overweight | $29 | $7.90 | +267.09% | 8 | May 17, 2024 | |
| ABEO Abeona Therapeutics | Maintains: Overweight | $28 → $21 | $4.38 | +379.45% | 6 | May 16, 2024 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $3.45 | +102.90% | 5 | May 16, 2024 | |
| CAPR Capricor Therapeutics | Reiterates: Overweight | $8 | $5.68 | +40.85% | 2 | May 14, 2024 | |
| ADMA ADMA Biologics | Maintains: Overweight | $8 → $10 | $9.55 | +4.71% | 5 | May 10, 2024 | |
| SRPT Sarepta Therapeutics | Reiterates: Neutral | $128 | $129.86 | -1.43% | 9 | May 2, 2024 | |
| ATNM Actinium Pharmaceuticals | Reiterates: Overweight | $21 | $8.15 | +157.67% | 3 | Apr 30, 2024 | |
| PTCT PTC Therapeutics | Reiterates: Overweight | $45 | $36.36 | +23.76% | 10 | Apr 12, 2024 | |
| HUMA Humacyte | Reiterates: Overweight | $7 | $7.48 | -6.42% | 5 | Apr 1, 2024 | |
| CLDX Celldex Therapeutics | Reiterates: Overweight | $67 | $33.30 | +101.20% | 7 | Mar 22, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $2 → $3 | $0.98 | +206.81% | 2 | Mar 6, 2024 | |
| FOLD Amicus Therapeutics | Reiterates: Overweight | $22 | $9.80 | +124.49% | 4 | Feb 29, 2024 | |
| LCTX Lineage Cell Therapeutics | Reiterates: Overweight | $6 | $1.00 | +500.00% | 3 | Feb 5, 2024 | |
| QURE uniQure | Reiterates: Overweight | $21 | $4.95 | +324.24% | 2 | Dec 20, 2023 | |
| SLNO Soleno Therapeutics | Maintains: Overweight | $19 → $35 | $42.08 | -16.83% | 3 | Sep 26, 2023 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | $90 → $20 | $7.07 | +182.89% | 2 | Aug 30, 2023 | |
| DRTS Alpha Tau Medical | Reiterates: Overweight | $23 | $2.51 | +816.33% | 2 | Aug 29, 2023 | |
| MBIO Mustang Bio | Reiterates: Overweight | $18 | $0.20 | +8,846.32% | 1 | Aug 24, 2023 | |
| OCUP Ocuphire Pharma | Reiterates: Overweight | $17 | $1.68 | +911.90% | 3 | Aug 14, 2023 | |
| DRRX DURECT | Maintains: Overweight | $44 → $41 | $1.71 | +2,297.66% | 2 | Aug 10, 2023 | |
| GLTO Galecto | Initiates: Overweight | $16 | $0.61 | +2,531.58% | 1 | Mar 17, 2023 | |
| IBIO iBio, Inc. | Downgrades: Neutral | $1,250 → $85 | $2.38 | +3,471.43% | 3 | Oct 7, 2022 | |
| HEPA Hepion Pharmaceuticals | Initiates: Overweight | $70 | $1.26 | +5,455.56% | 1 | Feb 28, 2022 | |
| EVLO Evelo Biosciences | Initiates: Overweight | n/a | $0.00 | - | 1 | Jun 23, 2021 | |
| CMMB Chemomab Therapeutics | Initiates: Overweight | n/a | $1.03 | - | 1 | May 26, 2021 | |
| OCGN Ocugen | Downgrades: Neutral | n/a | $1.73 | - | 3 | May 7, 2021 | |
| MRKR Marker Therapeutics | Initiates: Overweight | n/a | $3.87 | - | 1 | Mar 19, 2021 | |
| EVGN Evogene | Initiates: Overweight | n/a | $0.74 | - | 1 | Dec 1, 2020 | |
| GLMD Galmed Pharmaceuticals | Assumes: Overweight | n/a | $0.37 | - | 1 | Jan 30, 2020 | |
| PHGE BiomX | Initiates: Overweight | n/a | $0.40 | - | 1 | Jan 9, 2020 |
X4 Pharmaceuticals
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.01
Upside: +395.05%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Overweight
Price Target: $107 → $115
Current: $40.14
Upside: +186.50%
Codexis
May 30, 2024
Initiates: Overweight
Price Target: $11
Current: $3.38
Upside: +225.44%
Disc Medicine
May 28, 2024
Reiterates: Overweight
Price Target: $85
Current: $33.95
Upside: +150.37%
Taysha Gene Therapies
May 28, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.43
Upside: +104.08%
Skye Bioscience
May 23, 2024
Initiates: Overweight
Price Target: $21
Current: $11.61
Upside: +80.88%
Fulcrum Therapeutics
May 20, 2024
Initiates: Overweight
Price Target: $23
Current: $7.85
Upside: +192.99%
89bio
May 17, 2024
Reiterates: Overweight
Price Target: $29
Current: $7.90
Upside: +267.09%
Abeona Therapeutics
May 16, 2024
Maintains: Overweight
Price Target: $28 → $21
Current: $4.38
Upside: +379.45%
Mereo BioPharma Group
May 16, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.45
Upside: +102.90%
Capricor Therapeutics
May 14, 2024
Reiterates: Overweight
Price Target: $8
Current: $5.68
Upside: +40.85%
ADMA Biologics
May 10, 2024
Maintains: Overweight
Price Target: $8 → $10
Current: $9.55
Upside: +4.71%
Sarepta Therapeutics
May 2, 2024
Reiterates: Neutral
Price Target: $128
Current: $129.86
Upside: -1.43%
Actinium Pharmaceuticals
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $8.15
Upside: +157.67%
PTC Therapeutics
Apr 12, 2024
Reiterates: Overweight
Price Target: $45
Current: $36.36
Upside: +23.76%
Humacyte
Apr 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $7.48
Upside: -6.42%
Celldex Therapeutics
Mar 22, 2024
Reiterates: Overweight
Price Target: $67
Current: $33.30
Upside: +101.20%
Rigel Pharmaceuticals
Mar 6, 2024
Maintains: Neutral
Price Target: $2 → $3
Current: $0.98
Upside: +206.81%
Amicus Therapeutics
Feb 29, 2024
Reiterates: Overweight
Price Target: $22
Current: $9.80
Upside: +124.49%
Lineage Cell Therapeutics
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $1.00
Upside: +500.00%
uniQure
Dec 20, 2023
Reiterates: Overweight
Price Target: $21
Current: $4.95
Upside: +324.24%
Soleno Therapeutics
Sep 26, 2023
Maintains: Overweight
Price Target: $19 → $35
Current: $42.08
Upside: -16.83%
Outlook Therapeutics
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $7.07
Upside: +182.89%
Alpha Tau Medical
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.51
Upside: +816.33%
Mustang Bio
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.20
Upside: +8,846.32%
Ocuphire Pharma
Aug 14, 2023
Reiterates: Overweight
Price Target: $17
Current: $1.68
Upside: +911.90%
DURECT
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $1.71
Upside: +2,297.66%
Galecto
Mar 17, 2023
Initiates: Overweight
Price Target: $16
Current: $0.61
Upside: +2,531.58%
iBio, Inc.
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.38
Upside: +3,471.43%
Hepion Pharmaceuticals
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $1.26
Upside: +5,455.56%
Evelo Biosciences
Jun 23, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.00
Upside: -
Chemomab Therapeutics
May 26, 2021
Initiates: Overweight
Price Target: n/a
Current: $1.03
Upside: -
Ocugen
May 7, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.73
Upside: -
Marker Therapeutics
Mar 19, 2021
Initiates: Overweight
Price Target: n/a
Current: $3.87
Upside: -
Evogene
Dec 1, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.74
Upside: -
Galmed Pharmaceuticals
Jan 30, 2020
Assumes: Overweight
Price Target: n/a
Current: $0.37
Upside: -
BiomX
Jan 9, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.40
Upside: -